Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Low-dose Decitabine in Refractory Aplastic Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~Subjects eligible for enrollment in the study should meet all of following criteria:~1. Diagnosis of acquired aplastic confirmed by peripheral blood and bone-marrow examinations.~2. Refractory to standard first-line immunosuppressive therapy for at least 6 months, including the combination of rabbit anti-thymocyte globulin (rATG) or porcine anti-lymphocyte globulin (pALG) and cyclosporine (CsA); or ineligible for rATG/ pALG and refractory to CsA alone.~3. Persistent decrease of blood cell count, including platelet \<30×10\^9/L, and/or hemoglobin \<90g/L, and/or absolute neutrophil count \<0.5×10\^9/L.~4. Age ≥12 years old.~5. An Eastern Cooperative Oncology Group performance status score of 0 to 2 at screening.~6. Patients or their legally authorized representatives who have provided written informed consent of their free will to participate in this study.~Exclusion criteria:~Subjects must be excluded from participating in this study if they meet any of the following criteria:~1. Diagnosis of inherited bone marrow failure disorders.~2. Bone marrow reticulin grade of ≥2.~3. Having a plan to take thrombopoietin (TPO) receptor agonists.~4. Having a plan to undergo hematopoietic stem cell transplantation within 1 year.~5. Subjects with hemolytic paroxysmal nocturnal hemoglobinuria clone.~6. Having abnormalities of cytogenetic abnormalities related to myelodysplastic syndrome except for +8 or 20q- or -Y.~7. Previous or concurrent active malignancies with chemoradiotherapy, except localized tumors diagnosed more than one year previously and treated surgically with curative intent.~8. Cytopenias secondary to any other non-hematological disorders (e.g., liver cirrhosis, active connective tissue disease, or chronic persistent infectious diseases).~9. Active infection not adequately responding to appropriate therapy.~10. Positive for anti-human immunodeficiency virus antibodies, or current infection of hepatitis B virus or hepatitis C virus at screening.~11. Concurrent condition of acute hemorrhage in gastrointestinal tract or respiratory tract, or central nervous system.~12. Dysfunction of liver: Alanine aminotransferase or aspartate aminotransferase or total bilirubin is more than 2.0 times the upper limit of laboratory normal range.~13. Dysfunction of renal: creatinine clear rate is less than 30ml/min.~14. Clinically significant dysfunction of heart: class Ⅲ or Ⅳ of the New York Heart Association classification.~15. Uncontrolled diabetes mellitus.~16. History of congestive heart failure, unstable angina pectoris, myocardial infarction, arterial or venous thrombosis within one year before enrollment.~17. Lactating or pregnant women or patients who have no intention of using oral contraceptives or birth control.~18. Subjects with psychiatric history or severe cerebrovascular disease with cognitive disorder.~19. Participating in other clinical trials within 4 weeks before enrollment.~20. Hypersensitivity to decitabine or its components.~21. A history of decitabine, azacitidine, or other demethylation agents.~22. Receiving TPO-receptor agonists within 1 month before enrollment (other than patients who are treated with TPO-receptor agonists and have no response after at least 4 months treatment).~23. Patients who are considered to be ineligible for the study by the investigator for reasons other than above.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Decitabine (Type: EXPERIMENTAL): Subjects will receive low-dose decitabine for 4 cycles and for another 6 cycles in extension study for patients achieving response during the first 4 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).